Navigation Links
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Date:10/6/2008

nd (FEV1), a standard measure of lung function, were observed with both the 50 and 100microg doses of NVA237. Early post-dose spirometry data suggested a more rapid onset of action than tiotropium. During the study, NVA237 was well tolerated with a good overall safety profile.

The other study evaluated the safety and tolerability of NVA237 (100 and 200microg once-daily) in 250 patients during 28 days of treatment. In this study, both doses were safe and well tolerated, with no clinically significant changes seen in vital signs or on other cardiac monitoring. NVA237 provided sustained 24-hour bronchodilation over the study period. The authors concluded that NVA237 should be further evaluated for the treatment of COPD.

The results of the latest studies are consistent with previous clinical studies with NVA237 which demonstrated a potentially faster onset of action than tiotropium (five minutes versus 20-30 minutes) and a good overall safety and tolerability profile.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am pleased that these two trials have further confirmed the clinical profile of NVA237 in terms of low side effects and fast onset of action and that the drug has been deemed worthy of further study."

Dr Chris Blackwell, Chief Executive of Vectura commented: "On the back of these encouraging results, we now look forward to the continued progress of NVA237, and the combination therapy, QVA149."

Notes for Editors:

About the NVA237 and QVA149 licence agreement with Novartis

Sosei and Vectura Group plc concluded a global development and commercialisation agreement with Novartis in April 2005 for their collaborative product NVA237. Novartis is responsible for developing and commercializing NVA237 both as a monotherapy and in combination with indacaterol, its once daily, long-acting beta-2 agonist, as QVA149.

Under the terms of the agreement, Sosei and Vectura to date have each received $15 million and
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
2. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
3. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
4. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
5. Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 24, 2015 Introduction ... indication-specific planning tools for radiosurgery/SBRT   ... aimed at enhancing the workflow for difficult to ... in 2013 - comes full circle with the ... These new Elements enable on-the-fly generation of consistent ...
(Date:4/24/2015)... , April 24, 2015 Hi-Tech ... that such was not the product of reliable scientific ... a reliable basis for allegations of adulteration. The ... on a false premise, or misguided hope, that ... these studies are contradicted by multiple other studies ...
(Date:4/24/2015)... Hospira, Inc. (NYSE: HSP ... therapies, spoke about the importance of extrapolation in bringing ... (EGA) annual European Biosimilars Group conference in ... the publication of a pivotal white paper titled, ... of biosimilars." Speaking at the EGA ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
... January 5, 2012 Orthopedic Implants are medical ... injured or troubled joints. Bone is the basic element of ... and assists in movement. Humans commonly suffer from physical fractures, ... or humerus. Treatment of these fractures often requires surgery to ...
... SAN DIEGO, Jan. 5, 2012 Cardium Therapeutics (NYSE Amex: ... entered into its first international agreement for the commercialization ... Cardium entered into a marketing and distribution agreement with ... Korea, for the commercialization of Excellagen Formulated Fibrillar Collagen ...
Cached Medicine Technology:Narang Medical Introduces NET Multifix Nails: Same Nail That Can be Used for Right and Left Legs 2Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea 2Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea 3Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea 4Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea 5Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea 6
(Date:4/26/2015)... India Network Foundation, a non-profit organization in the ... the Asian Indian community in the United States and ... two decades. The India News Network Digest of 1990s ... world with the latest news items from India, the ... Forum Digest, edited and contributed by Sheela Murthy, helped ...
(Date:4/26/2015)... Petersburg, FL (PRWEB) April 26, 2015 ... Diego, California. The city is one which is synonymous with ... Tourism, international trade, and education are major economic influencers in ... Producers of the dynamic talk show are pleased to announce ... on Sunday, April 26 at 3:00 PM PDT. Tune in ...
(Date:4/25/2015)... The National League for Nursing's Advancing Care ... prepare nurses to provide high quality, culturally sensitive care ... a new report by the John A. Hartford Foundation, ... The project began in 2007 as a pilot at ... Elaine Tagliareni, EdD, RN, CNE, FAAN, professor and Independence ...
(Date:4/25/2015)... In observance of World Malaria Day, today ... Pledge, a two-year pledge by the United Nations Foundation’s ... one million bednets by 2016. This ambitious $10 million ... to protect children, refugees, and families displaced by conflict ... been a large surge in refugee families displaced by ...
(Date:4/25/2015)... York, New York (PRWEB) April 25, 2015 ... ) established for vaginal mesh lawsuits filed against ... the U.S. District Court, Southern District of West ... 9th, a Scheduling Conference was convened that day, ... Plaintiffs’ Master Long Form Complaint. The Order directed ...
Breaking Medicine News(10 mins):Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:Forbes Living TV Will Air in San Diego, California 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4
... Health Common User Interface will help, increase clinician efficiency ... ... Wash., Sept. 10 Healthcare,developers will be able to increase ... User Interface (CUI),available today from Microsoft Corp. The guidance and ...
... School of Medicine have developed a molecular probe that ... is to use the probe to improve the diagnosis ... probe,s main ingredient is a molecule that labels active ... cancerous cells. The molecule is normally invisible to the ...
... PAINWeek 2007 Said Most Patients ... VEGAS, Sept. 8 In addition to reporting a ... surveyed,during PAINWeek 2007 said treating pain will improve insomnia ... Nearly 98 percent of those polled said they believed ...
... Sets Better Ability to Improve Patient Care, ... St.,Francis Medical Center have reached a tentative agreement ... that will increase their ability to,advocate for improved ... of a qualified and skilled staff. The ...
... 2007 Inc. 500, LAS VEGAS, Sept. 7 Inc. ... Inc. 500 list of the fastest-growing,private companies in the U.S. ... that same category, achieved a record three year sales growth ... "If you want to find out which companies are going ...
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... treatment of venous reflux disease, today,announced the resignation ... President, Finance & Administration, to be effective October ... begun a search for a,new chief financial officer. ...
Cached Medicine News:Health News:Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit 2Health News:Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit 3Health News:Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit 4Health News:Molecular probe 'paints' cancer cells in living animals, Stanford researchers find 2Health News:Molecular probe 'paints' cancer cells in living animals, Stanford researchers find 3Health News:Link Between Chronic Pain and Insomnia Uncovered at PAINWeek 2007 2Health News:Link Between Chronic Pain and Insomnia Uncovered at PAINWeek 2007 3Health News:Workers Win Contract at St. Francis Medical Center 2Health News:Inc. Magazine Reveals Its 26th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:Inc. Magazine Reveals Its 26th Annual List of America's 500 Fastest-Growing Private Companies 3
... The Chalam Flat is ... nerve neurotomy and induction of ... also useful for macula whole ... removal of tractional epiretinal membranes. ...
... 1.5x is specifically designed ... peeling in macular hole ... sheathotomy and macularepiretinal membrane ... and other situations warranting ...
... ACS lenses offer the high resolution, high ... original clariVits. The simple two part design ... integrity during surgery. Simply autoclave, add saline ... lock together for use. (ACS) AutoClave Sterilizable ...
... offers high resolution by far surpassing ... in stereopsis, brilliance and clarity, detailed ... in diabetics, membrane peeling extending to ... Sterilizable Lenses The ACS Vitrectomy Lenses ...
Medicine Products: